ClinVar Miner

Submissions for variant NM_007294.4(BRCA1):c.5091T>G (p.Cys1697Trp)

dbSNP: rs1597820426
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000985428 SCV001133608 uncertain significance not provided 2019-03-25 criteria provided, single submitter clinical testing
Invitae RCV003530120 SCV004314120 likely pathogenic Hereditary breast ovarian cancer syndrome 2023-07-30 criteria provided, single submitter clinical testing This variant is not present in population databases (gnomAD no frequency). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Cys1697 amino acid residue in BRCA1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 11157798, 11389159, 18465347). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling performed at Invitae incorporating data from internal and/or published experimental studies (PMID: 30209399) indicates that this missense variant is expected to disrupt BRCA1 function. ClinVar contains an entry for this variant (Variation ID: 801082). This variant has not been reported in the literature in individuals affected with BRCA1-related conditions. This sequence change replaces cysteine, which is neutral and slightly polar, with tryptophan, which is neutral and slightly polar, at codon 1697 of the BRCA1 protein (p.Cys1697Trp).
Institute of Immunology and Genetics Kaiserslautern RCV001077567 SCV004363617 uncertain significance Breast-ovarian cancer, familial, susceptibility to, 1 2024-02-02 criteria provided, single submitter clinical testing ACMG Criteria: PM2_P, PP3; Variant was found in heterozygous state
Brotman Baty Institute, University of Washington RCV001077567 SCV001243517 not provided Breast-ovarian cancer, familial, susceptibility to, 1 no assertion provided in vitro

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.